Eton Pharmaceutcials (ETON) Stock: Buy, Sell, or Hold?
ETON - Eton Pharmaceutcials, Inc. Common Stock
$49.52
0.22 (0.45%)
▲
5d:
-3.53%
30d:
-10.95%
90d:
+16.27%
BUY
MODERATE Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 05, 2026
13d
Get Alerted When ETON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ETON shows positive signals but monitor for confirmation. Market pricing in 1.7% growth. Moderate conviction.
💡 BUY OPPORTUNITY: ETON shows positive signals but monitor for confirmation. Market pricing in 1.7% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$91.37
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$56.73
12.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ETON is currently trading at $49.52, which is considered oversold relative to its 30-day fair value range of $51.52 to $57.47. The stock's valuation (Forward PE: 19.3) is in line with its historical norms (18.4). At these levels, the market is pricing in 1.7% annual earnings growth.
Technical Outlook: Technically, ETON is in a strong uptrend. The price is currently testing key support at $48.36. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ETON scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $71.50 (+45.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ETON is in a strong uptrend. The price is currently testing key support at $48.36. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ETON scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $71.50 (+45.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$51.52 -
$57.47
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
95.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 45.0% below Wall St target ($71.50)
- BULLISH: Expecting earnings turnaround to 1.7% growth with 98.6% revenue growth
- BULLISH: Bottoming setup score 65/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$51.52 -
$57.47
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$5.67
(11.4%)
Support & Resistance Levels
Support Level
$48.36
Resistance Level
$57.00
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.33
Wall Street Target
$71.50
(+45.0%)
Revenue Growth (YoY)
98.6%
Earnings Growth (YoY)
-12.6%
Profit Margin
12.0%
Valuation Premium vs History
+1.7% premium
PE vs Historical
19.3 vs 18.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.7%
(market-implied from PE analysis)
1-Year Target
$50.14
(+2%)
2-Year Target
$50.99
(+3%)
3-Year Target
$51.86
(+5%)
3-Yr Target (if PE normalizes)
(PE: 19→18)
PE COMPRESSION
$49.35
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 82.1%)
$170.92
(+247%)
Base:
(SPY PE: 19.3, Growth: 82.1%)
$166.39
(+238%)
Bear:
(PE: 16.4, Growth: 82.1%)
$141.43
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (19x PE) as earnings recover.
Forward PE: 23.92 | Forward EPS (Implied): $2.06
Bull Case
$59.53
(+21%)
Analyst growth 15.0%, PE expands to 25.1
Base Case
$49.30
(0%)
Market implied 0.0%, PE stable at 23.9
Bear Case
$37.71
(-24%)
Severe decline -15.0%, PE contracts to 21.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 22, 2026 12:50 PM ET
Data refreshes hourly during market hours. Next update: 1:50 PM
Data refreshes hourly during market hours. Next update: 1:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ETON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 60 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 49 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 43 HOLD |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 59 HOLD |
